PMID- 2123126
OWN - NLM
STAT- MEDLINE
DCOM- 19910107
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 66
IP  - 11
DP  - 1990 Dec 1
TI  - Growth-inhibitory effect of combination chemotherapy for human pancreatic cancer 
      cell lines.
PG  - 2369-74
AB  - Sensitivities to anti-tumor drugs, mitomycin C (MMC), aclarubicin hydrochloride 
      (ACR), doxorubicin hydrochloride (ADR), cisplatin, and 5-fluorouracil (5FU), were 
      examined using PK-1, -8, -9, -12, -14, and -16 cell lines derived from human 
      pancreatic cancer. These cell lines showed different sensitivities to each of the 
      above anti-tumor drugs. The concentrations required for 50% growth-inhibition 
      (IC50) after 2 hours of exposure were 0.096 to 0.35 micrograms/ml for MMC, 0.0074 
      to 0.0076 micrograms/ml for ACR, 0.033 to 0.23 micrograms/ml for ADR, 0.35 to 1.9 
      micrograms/ml for cisplatin, and 21 to 42 micrograms/ml for 5FU, IC50 of each 
      anti-tumor drug decreased significantly after 48 hours of exposure. The 
      combination of any two out of MMC, ACR, and 5FU showed synergistic inhibition of 
      the growth of PK-1 and PK-8 cell lines. These results show that MMC, ACR, ADR, 
      cisplatin, and 5FU have sufficient anti-tumor effect against six human pancreatic 
      cancer cell lines even at clinically achievable concentrations and exposure 
      times, and chemotherapy for pancreatic cancers requires naturally effective drug 
      delivery into cancer tissues.
FAU - Matsuno, S
AU  - Matsuno S
AD  - First Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.
FAU - Hisano, H
AU  - Hisano H
FAU - Kobari, M
AU  - Kobari M
FAU - Akaishi, S
AU  - Akaishi S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Mitomycins)
RN  - 50SG953SK6 (Mitomycin)
RN  - 74KXF8I502 (Aclarubicin)
RN  - 80168379AG (Doxorubicin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aclarubicin/administration & dosage
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma/*drug therapy
MH  - Cell Division/*drug effects
MH  - Cisplatin/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Doxorubicin/administration & dosage
MH  - Drug Synergism
MH  - Fluorouracil/administration & dosage
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Mitomycin
MH  - Mitomycins/administration & dosage
MH  - Pancreatic Neoplasms/*drug therapy
MH  - Tumor Cells, Cultured
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
AID - 10.1002/1097-0142(19901201)66:11<2369::aid-cncr2820661120>3.0.co;2-z [doi]
PST - ppublish
SO  - Cancer. 1990 Dec 1;66(11):2369-74. doi: 
      10.1002/1097-0142(19901201)66:11<2369::aid-cncr2820661120>3.0.co;2-z.